TABLE 2.
Inhibition of primary HIV-1 Env isolates by CD4-mimetic compounds in the presence of 17b CD4i antibody or plasma from immunized monkeys
| Antibody/compound | IC50 fora: |
|||
|---|---|---|---|---|
| HIV-1JR-FL | HIV-1YU2 | HIV-1AD8 | A-MLV | |
| BNM-III-170b | 17.4 μM | 1.9 μM | 3.6 μM | >100 μM |
| 17b | >30 μg/ml | >30 μg/ml | >30 μg/ml | >30 μg/ml |
| NHP 79-5356, wk 21 | >1:80 | >1:80 | >1:80 | 1:160 |
| NHP 62.1-5097, wk 123 | >1:80 | >1:80 | >1:80 | 1:160 |
| NHP 109-6117, wk 71 | >1:80 | >1:80 | >1:80 | >1:80 |
| NHP 109-6204, wk 71 | >1:80 | >1:80 | >1:80 | 1:160 |
| 17b + BNM-III-170 | 0.2 μg/ml | <0.2 μg/ml | 0.2 μg/ml | >30 μg/ml |
| NHP 79-5356, wk 21, + BNM-III-170 | 1:320 | 1:640 | 1:640 | 1:80 |
| NHP 62.1-5097, wk 123, + BNM-III-170 | 1:640 | 1:1,280 | 1:1,280 | >1:80 |
| NHP 109-6117, wk 71, + BNM-III-170 | 1:1,280 | 1:1,280 | 1:1,280 | >1:80 |
| NHP 109-6204, wk 71, + BNM-III-170 | 1:640 | 1:1,280 | 1:1,280 | 1:160 |
Recombinant HIV-1 encoding firefly luciferase was pseudotyped with the indicated HIV-1 Env (or A-MLV Env control), as described in the footnotes to Table 1. Viruses were incubated with 10 μM BNM-III-170 (YU2 and AD8), 50 μM BNM-III-170 (JR-FL and A-MLV), or DMSO and then with different concentrations of the 17b antibody or dilution of plasma. The nonhuman primates (NHP) 6117 and 6204 were subjects in CHAVI-ID NHP 109, and both were members of group 1, which received basiliximab (1 mg) after immunization with CH505 T/F gp120 in GLA-SE adjuvant. The concentration of the 17b antibody (μg/ml) or the titer of the plasma that neutralized 50% of the virus infection is indicated. Means and standard deviations from triplicate samples within an experiment are shown.
The inhibitory concentration (IC50) for the direct antiviral effect of BNM-III-170 was determined as described in footnote a.